Tanabe Pharma Corporation
Clinical trials sponsored by Tanabe Pharma Corporation, explained in plain language.
-
New hope for tough lymphoma: experimental drug MT-2111 targets relapsed DLBCL
Disease control OngoingThis study tests a new drug called MT-2111 for people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has returned or not improved after at least two prior treatments. The first part of the study finds a safe dose, and the second part checks if the d…
Phase: PHASE1, PHASE2 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New drug shows promise for rare Skin-Hardening disease
Disease control OngoingThis study tests a new medicine called MT-0551 to see if it can reduce skin thickening in people with systemic sclerosis, a rare disease that causes the skin to harden and tighten. About 80 adults with moderate skin thickening will receive either the drug or a placebo for 26 week…
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated May 07, 2026 18:39 UTC